Inventiva SA
PAR:IVA

Watchlist Manager
Inventiva SA Logo
Inventiva SA
PAR:IVA
Watchlist
Price: 3.76 EUR -1.31%
Market Cap: 718.2m EUR
Section:
 

Relative Value

The Relative Value of one IVA stock under the Base Case scenario is 1.99 EUR. Compared to the current market price of 3.76 EUR, Inventiva SA is Overvalued by 47%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IVA Relative Value
Base Case
1.99 EUR
Overvaluation 47%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

53.5
P/S
P/S
Price to Sales
53.5
vs History
58
vs Industry
34
Median 3Y
49.4
Median 5Y
63.9
Industry
7.9
Forward
123.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5.1
Median 5Y
-7.6
Industry
24
Forward
-3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-7.7
Median 5Y
-12.3
Industry
21.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-8.3
Median 5Y
-16.9
Industry
23.7
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
19
Median 3Y
-5.7
Median 5Y
9.1
Industry
3.4
More Details
49.9
EV/S
EV/S
Enterprise Value to Sales
49.9
vs History
63
vs Industry
27
Median 3Y
47
Median 5Y
60.3
Industry
8.3
Forward
115.5
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-6.4
Median 5Y
-9.9
Industry
6.7
Forward
-6.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-6.2
Median 5Y
-9.2
Industry
7.2
Forward
-6.1
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-7.8
Median 5Y
-11.7
Industry
8.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-7.8
Median 5Y
-11.6
Industry
6.7
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
10
Median 3Y
36
Median 5Y
65.8
Industry
5.7
More Details

Multiples Across Competitors

IVA Competitors Multiples
Inventiva SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Inventiva SA
PAR:IVA
727.8m EUR 53.5 -2.3 -7.5 -6.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 924 975 -161 240.4 -195 797.2 -193 563
US
Abbvie Inc
NYSE:ABBV
398B USD 6.7 169.5 16.4 23.3
US
Amgen Inc
NASDAQ:AMGN
169.7B USD 4.7 24.2 17.6 17.6
US
Gilead Sciences Inc
NASDAQ:GILD
150.7B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.9B USD 9.6 30.7 22.5 23.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 076.6 -529.9 -577 -561.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.5B USD 5.4 16.7 15.9 18
AU
CSL Ltd
ASX:CSL
86.6B AUD 3.7 19.3 13 16.2
NL
argenx SE
XBRU:ARGX
46.4B EUR 15.1 35.5 61.2 62.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.3B USD 16.6 1 223.6 160.8 195
P/S Multiple
Revenue Growth P/S to Growth
FR
Inventiva SA
PAR:IVA
Average P/S: 3 084 288.4
53.5
48%
1.1
FR
Pharnext SCA
OTC:PNEXF
33 924 975
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
5%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
10%
1
US
E
Epizyme Inc
F:EPE
2 076.6
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.4
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
NL
argenx SE
XBRU:ARGX
15.1
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.6
46%
0.4
P/E Multiple
Earnings Growth PEG
FR
Inventiva SA
PAR:IVA
Average P/E: 192.3
Negative Multiple: -2.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 240.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
169.5
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.2
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.7
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
9%
1.9
AU
CSL Ltd
ASX:CSL
19.3
11%
1.8
NL
argenx SE
XBRU:ARGX
35.5
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 223.6
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Inventiva SA
PAR:IVA
Average EV/EBITDA: 40
Negative Multiple: -7.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 797.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.6
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
11%
1.4
AU
CSL Ltd
ASX:CSL
13
8%
1.6
NL
argenx SE
XBRU:ARGX
61.2
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
160.8
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Inventiva SA
PAR:IVA
Average EV/EBIT: 46.1
Negative Multiple: -6.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 563 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.3
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.6
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
13%
1.4
AU
CSL Ltd
ASX:CSL
16.2
11%
1.5
NL
argenx SE
XBRU:ARGX
62.9
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
195
N/A N/A

See Also

Summary
IVA intrinsic value, competitors valuation, and company profile.
DCF Valuation
IVA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IVA stock valuation using valuation multiples.
Wall Street Estimates
IVA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IVA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 302,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.